171 related articles for article (PubMed ID: 16146813)
1. Survivin expression in intracranial ependymomas and its correlation with tumor cell proliferation and patient outcome.
Preusser M; Wolfsberger S; Czech T; Slavc I; Budka H; Hainfellner JA
Am J Clin Pathol; 2005 Oct; 124(4):543-9. PubMed ID: 16146813
[TBL] [Abstract][Full Text] [Related]
2. No prognostic impact of survivin expression in glioblastoma.
Preusser M; Gelpi E; Matej R; Marosi C; Dieckmann K; Rössler K; Budka H; Hainfellner JA
Acta Neuropathol; 2005 May; 109(5):534-8. PubMed ID: 15843906
[TBL] [Abstract][Full Text] [Related]
3. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors.
Sui L; Dong Y; Ohno M; Watanabe Y; Sugimoto K; Tokuda M
Int J Oncol; 2002 Aug; 21(2):315-20. PubMed ID: 12118327
[TBL] [Abstract][Full Text] [Related]
4. Topoisomerase IIalpha expression as an independent prognostic factor in Hodgkin's lymphoma.
Doussis-Anagnostopoulou IA; Vassilakopoulos TP; Thymara I; Korkolopoulou P; Angelopoulou MK; Siakantaris MP; Kokoris SI; Dimitriadou EM; Kalpadakis C; Matzouranis M; Kaklamanis L; Panayiotidis P; Kyrtsonis MC; Androulaki A; Patsouris E; Kittas C; Pangalis GA
Clin Cancer Res; 2008 Mar; 14(6):1759-66. PubMed ID: 18347177
[TBL] [Abstract][Full Text] [Related]
5. Expression of survivin correlated with vessel invasion is a marker of poor prognosis in small adenocarcinoma of the lung.
Ikehara M; Oshita F; Kameda Y; Ito H; Ohgane N; Suzuki R; Saito H; Yamada K; Noda K; Mitsuda A
Oncol Rep; 2002; 9(4):835-8. PubMed ID: 12066218
[TBL] [Abstract][Full Text] [Related]
6. Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease.
Grabowski P; Griss S; Arnold CN; Hörsch D; Göke R; Arnold R; Heine B; Stein H; Zeitz M; Scherübl H
Neuroendocrinology; 2005; 81(1):1-9. PubMed ID: 15809513
[TBL] [Abstract][Full Text] [Related]
7. Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors.
Zamecnik J; Snuderl M; Eckschlager T; Chanova M; Hladikova M; Tichy M; Kodet R
Mod Pathol; 2003 Oct; 16(10):980-91. PubMed ID: 14559980
[TBL] [Abstract][Full Text] [Related]
8. Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma.
Wolfsberger S; Fischer I; Höftberger R; Birner P; Slavc I; Dieckmann K; Czech T; Budka H; Hainfellner J
Am J Surg Pathol; 2004 Jul; 28(7):914-20. PubMed ID: 15223962
[TBL] [Abstract][Full Text] [Related]
9. Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker.
Preusser M; Heinzl H; Gelpi E; Höftberger R; Fischer I; Pipp I; Milenkovic I; Wöhrer A; Popovici F; Wolfsberger S; Hainfellner JA
Histopathology; 2008 Jul; 53(1):39-47. PubMed ID: 18613924
[TBL] [Abstract][Full Text] [Related]
10. Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas.
Kurt E; Zheng PP; Hop WC; van der Weiden M; Bol M; van den Bent MJ; Avezaat CJ; Kros JM
Cancer; 2006 Jan; 106(2):388-95. PubMed ID: 16342252
[TBL] [Abstract][Full Text] [Related]
11. DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: correlation with MIB1 expression and patient survival.
Holden JA; Townsend JJ
Mod Pathol; 1999 Dec; 12(12):1094-100. PubMed ID: 10619260
[TBL] [Abstract][Full Text] [Related]
12. Tumor vessel biology in pediatric intracranial ependymoma.
Wagemakers M; Sie M; Hoving EW; Molema G; de Bont ES; den Dunnen WF
J Neurosurg Pediatr; 2010 Apr; 5(4):335-41. PubMed ID: 20367336
[TBL] [Abstract][Full Text] [Related]
13. Survivin expression and its relationship with apoptosis and prognosis in nasal and paranasal sinus carcinomas.
Zhang Y; Huang D; Yu G
Acta Otolaryngol; 2005 Dec; 125(12):1345-50. PubMed ID: 16303685
[TBL] [Abstract][Full Text] [Related]
14. Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas.
Zhen HN; Zhang X; Hu PZ; Yang TT; Fei Z; Zhang JN; Fu LA; He XS; Ma FC; Wang XL
Cancer; 2005 Dec; 104(12):2775-83. PubMed ID: 16284993
[TBL] [Abstract][Full Text] [Related]
15. Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma.
Kleinberg L; Flørenes VA; Silins I; Haug K; Trope CG; Nesland JM; Davidson B
Cancer; 2007 Jan; 109(2):228-38. PubMed ID: 17167759
[TBL] [Abstract][Full Text] [Related]
16. Histological spectrum of ependymomas and correlation of p53 and Ki-67 expression with ependymoma grade and subtype.
Suri VS; Tatke M; Singh D; Sharma A
Indian J Cancer; 2004; 41(2):66-71. PubMed ID: 15318011
[TBL] [Abstract][Full Text] [Related]
17. Prognosis of glioma patients by combined immunostaining for survivin, Ki-67 and epidermal growth factor receptor.
Kogiku M; Ohsawa I; Matsumoto K; Sugisaki Y; Takahashi H; Teramoto A; Ohta S
J Clin Neurosci; 2008 Nov; 15(11):1198-203. PubMed ID: 18835716
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical study on topoisomerase IIalpha, Ki-67 and cytokeratin-19 in oral lichen planus lesions.
Mattila R; Alanen K; Syrjänen S
Arch Dermatol Res; 2007 Jan; 298(8):381-8. PubMed ID: 17072627
[TBL] [Abstract][Full Text] [Related]
19. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase-2 (cox-2) expression and angiogenesis in intracranial ependymomas.
Onguru O; Kurt B; Gunhan O; Soylemezoglu F
Clin Neuropathol; 2006; 25(5):216-20. PubMed ID: 17007443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
